Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.
Bayer pharmaceuticals executive Marianne De Backer will succeed Scangos at Vir, tasked with advancing several mid-stage programs in areas like hepatitis B and influenza to late-stage development.
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
Emerging Company Profile: The UK biotech is working to expedite its portfolio of acquired drug candidates for cancer through the clinic before out-licensing to big pharma in a bid to bring patients the treatments they need sooner rather than later.
Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.
Investors, advisors and CEOs at the J.P. Morgan Healthcare Conference and Biotech Showcase were somewhat optimistic about fundraising this year, but noted certain companies may have to call it quits.
As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.
US Innovative Medicines president Victor Bulto talked to Scrip about why the company is pivoting to a commercial strategy that prioritizes the US and what that means for developing and selling drugs.
Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.